Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoStem has announced that its Suzhou Erye Pharmaceutical subsidiary (Erye) received approval from the State Food and Drug Administration (SFDA) in China, to manufacture solvent crystallization sterile penicillin and freeze dried raw sterile penicillin at their new facility.
Subscribe to our email newsletter
The company said that its new facility provides 50% and 100% greater manufacturing capacity, respectively, than its existing facility.
Robin Smith, chairman and CEO of NeoStem, said: “This also is the beginning of Erye’s relocation of operations to the new facility, which will continue through 2011, as the new production lines are completed and receive cGMP certification.
“Once Erye has completed its relocation to the new facility, and its new production lines are fully operational, it will have substantially increased its capacity from the current plant with the goal of becoming among the largest antibiotic producers in Eastern China.”
NeoStem is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the US and China.